Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Elberry, Ahmed A ^a   Mufti, Shagufta T ^b   Al Maghrabi, Jaudah A ^b   Abdel Sattar, Essam A ^c   Ashour, Osama M ^a   Ghareib, Salah A ^a   Mosli, Hisham A ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Aziz University   (Saudi Arabia)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

anti inflammatory; antiproliferative; atypical prostatic hyperplasia; castration; citral; cytokines; date palm pollen; immunohistochemistry

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CLUSTERIN; HERBACEOUS AGENT; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; PHOENIX DACTYLIFERA EXTRACT; PLANT EXTRACT; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; ORGAN WEIGHT; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SABAL;

PHOENIX DACTYLIFERA; RATTUS; RATTUS NORVEGICUS; SERENOA REPENS;

EID: 84155173325     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-40     Document Type: Article

References (47)

1. A signaling network in phenylephrine-induced benign prostatic hyperplasia. Kim J, Yanagihara Y, Kikugawa T, Ji M, Tanji N, Masayoshi Y, Freeman MR, Endocrinology 2009 150 3576 3583 10.1210/en.2008-1782 19443575
2. The biological significance of atypical hyperplasia of the prostate. Helpap B, Virchows Arch A Pathol Anat Histol 1980 387 307 317 10.1007/BF00454834 7456316 (Pubitemid 10032288)
3. Prostate growth and inflammation. Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, Di Silverio F, J Steroid Biochem Mol Biol 2008 108 254 260 10.1016/j.jsbmb.2007.09.013 2214787 (Pubitemid 351179630)
4. Inflammation, apoptosis, and BPH: What is the evidence? Novara G, Galfano A, Berto RB, Ficarra V, Navarrete RV, Artibani W, Eur Urol Suppl 2006 5 401 409 10.1016/j.eursup.2006.02.003 (Pubitemid 43340414)
5. Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Wang L, Yang J, Yang L, Liu Z, Medical Hypotheses 2008 70 1021 1023 10.1016/j.mehy.2007.08.022 17935901 (Pubitemid 351400693)
6. Prostate cancer and chronic prostatitis. Sandhu JS, Current Urol Reports 2008 9 328 332 10.1007/s11934-008-0056-6
7. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Fernandez F, de Beer PM, van der Merwe L, Heyns CF, Carcinogenesis 2008 29 2347 2350 10.1093/carcin/bgn245 18974063
8. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Rigas B, Sun Y, Br J Cancer 2008 98 1157 1160 10.1038/sj.bjc.6604225 18253125 (Pubitemid 351481667)
9. Effect of Phoenix Dactylifera Pollen on Sperm Parameters and Reproductive system of Adult Male Rats. Bahmanpour S, Talaei T, Vojdani Z, Panjehshahin MR, Poostpasand A, Zareei S, Ghaeminia M, Iran J Med Sci 2006 31 208 212 (Pubitemid 44904587)
10. The gonad stimulating potency of date palm pollen grains. Soliman FA, Soliman A, Experientia 1958 14 92 93 10.1007/BF02159230 13537883
11. Ethnobotany of Phoenix (Arecaceae). Bajpayee KK, JETB 1997 21 155 157
12. Sperm motion parameters in vas deferens and cauda epididymal rat sperm. Dostal LA, Faber CK, Zandee J, Reprod Toxicol 1996 10 231 235 10.1016/0890-6238(96)00027-5 8738561 (Pubitemid 126657489)
13. Therapeutic results of defined pollen extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. Ebeling L, Therapy of prostatitis Zuckschwerdt Verlag, MiInchen, Schmiedt E, Alken JE, Bauer H W, 1986 154 160
14. Treatment of chronic prostatitis and prostatodynia with pollen extract. Buck AC, Rees RWM, Ebeling L, Br J Urol 1989 64 496 499 10.1111/j.1464-410X. 1989.tb05285.x 2692777 (Pubitemid 20018591)
15. Induction of Atypical Prostatic Hyperplasia in Rats by Sympathomimetic Stimulation. Golomb E, Kruglikova A, Dvir D, Parnes N, Abramovici A, Prostate 1998 34 214 221 10.1002/(SICI)1097-0045(19980215)34:3<214::AID-PROS9>3.0. CO;2-H 9492850 (Pubitemid 28156612)
16. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Sandford NL, Searle JW, Kerr JF, Pathol 1984 16 406 410 10.3109/00313028409084731 (Pubitemid 15193322)
17. Citral and testosterone interaction in inducing benign and atypical prostatic hyperplasia in rats. Engelstein D, Shmueli J, Bruhis S, Servadio C, Abramovici A, Comp Biochem Physiol 1996 115 169 177 10.1016/0300-9629(96)00030-8 (Pubitemid 26302030)
18. Comparative Study of Experimentally Induced Benign and Atypical Hyperplasia in the Ventral Prostate of Different Rat Strains. Scolnik MD, Servadio C, Abramovici A, J Androl 1994 15 287 297 7527017 (Pubitemid 24256641)
19. "Histopathologic Techniques and Practical Histochemistry". Lillie RD, McGraw-Hill, New York 1965
20. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A, Eur Urol 2011 60 106 1017 10.1016/j.eururo.2011.03.055 21497433
21. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Bartsch G, Culig Z, J Pathol 2000 191 239 244 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X 10878544 (Pubitemid 30441246)
22. Prostate cancer immunohistochemical (IHC) stains and survival in stage D3 patients (pts). Gounder SK, Chang VT, Hoover D, Gonzalez ML, Ahmed S, Finch-Cruz C, Duque L, Zhong F, Toomey K, Kasimis BS, J Clin Oncol 2008 26 22187
23. The association of benign prostatic hyperplasia and cancer of the prostate. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP, Cancer 1992 70 291 301 10.1002/1097-0142(19920701)70:1+<291::AID- CNCR2820701317>3.0.CO;2-4 1376199
24. Experimental induction of atypical hyperplasia in rat ventral prostate. Abramovici A, Servadio C, Shmuely J, Sandbank U, Prostate Cancer. Part A: Research. Endocrine Treatment and Histopathology Alan R Liss, New York, Murphy GP, Khoun S, 1987 559 568
25. Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. Geldof AA, Enel C, Rao BR, Urol Res 1992 20 139 144 10.1007/BF00296526 1372772
26. Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tissue. Brolin J, Skoog L, Ekman P, Prostate 1992 20 281 295 10.1002/pros.2990200404 1376911
27. Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostate of noble rats treated with testosterone and pharmacologic doses of estradiol-17 Hoe S, Leav I, Merk FB, Yu M, Kwan PW, Ziar J, Lab Invest 1995 73 356 365 7564268
28. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Soulitzis N, Karyotis I, Delakas D, Spandidos DA, Int J Oncol 2006 29 305 314 16820871
29. Mechanistic Investigation of the Adrenergic Induction Of Ventral Prostate Hyperplasia in Mice. Marinese D, Patel R, Walden PD, Prostate 2003 54 230 237 10.1002/pros.10170 12518328 (Pubitemid 36120321)
30. Effect of Epristeride on the Expression of IGF-1 and TGF-beta Receptors in Androgen-Induced Castrated Rat Prostate. Wu S, Sun H, Qi X, Tu Z, Exp Biol Med 2001 226 954 960
31. The type II insulin-like growth factor receptor does not mediate deoxyribonucleic synthesis in human fibroblasts. Furlanetto RW, Dicarlo JN, Wisehart C, J Clin Endocrinol Metab 1987 64 1142 1149 10.1210/jcem-64-6-1142 2952664 (Pubitemid 17074770)
32. Regulation of prostatic growth and function by peptide growth factors. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocke H, Prostate 1996 28 392 405 10.1002/(SICI)1097-0045(199606)28: 6<392::AID-PROS9>3.0.CO;2-C 8650077 (Pubitemid 26187724)
33. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Kramer G, Marberger M, Curr Opin Urol 2006 16 25 29 16385197 (Pubitemid 43041217)
34. Inflammation and chronic prostatic diseases: evidence for a link? Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V, Eur Urol 2007 52 964 972 10.1016/j.eururo.2007.06.038 17618043 (Pubitemid 47332058)
35. Interleukin-6 is an autocrine growth factor in human prostate cancer. Giri D, Ozen M, Ittmann M, Am J Path 2001 159 2159 2165 10.1016/S0002-9440(10) 63067-2 11733366 (Pubitemid 33104270)
36. Complex Mechanisms in Prostatic Inflammatory Response. Djavan B, Eckersberger E, Espinosa G, Kramer G, Handisurya A, Lee C, Marberger M, Lepor H, Steiner GE, Eur Urol Suppl 2009 8 872 878 10.1016/j.eursup.2009.11.003
37. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D, Urology 1999 53 139 47 10.1016/S0090-4295(98)00455-5 9886603 (Pubitemid 29016629)
38. Interleukin 1a and tumor necrosis factor-a induce oxygen radical production in mesangial cells. Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K, J Clin Invest 1990 37 767 775 (Pubitemid 20056850)
39. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. Descazeaud A, Weinbreck N, Robert G, Vacherot F, Abbou CC, Labrousse F, Allory Y, Rubin MA, de la Taille A, BJU Int 2011 108 2Pt 2 23 E28 20840324
40. Cemitin pollenextract (Cernilton) Antiprostatic hypertrophic action of Cernitin pollen-extract (Cernilton). Ito R, Ishii A, Yamashita S, Pharmacometrics (Jpn.) 1986 31 1 11 (Pubitemid 16133916)
41. Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig. Kimura M, Kimura I, Nakase K, Planta Med 1986 2 148 151 3725935 (Pubitemid 16110504)
42. Prostatodynia-physiological characteristics and rational management with muscle relaxants. Osborn DE, George NJR, Rao PN, Brit J Urol 1981 53 621 623 10.1111/j.1464-410X.1981.tb03275.x 7032641 (Pubitemid 12251334)
43. Inhibitory effect and synergism of cernitin pollen extract on the urethral smooth muscle and diaphragm of the rat. Nakase K, Takenaga K, Hamanaka T, Kimura M, Nippon Yakurigaku Zasshi 1988 91 385 392 10.1254/fpj.91.385 3417212
44. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo controlled study. Buck AC, Cox R, Rees RW, Ebeling L, John A, Br J Urol 1990 66 398 404 10.1111/j.1464-410X.1990.tb14962.x 1699628 (Pubitemid 20342715)
45. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. Vacher P, Prevarskaya N, Skryma R, Audy MC, Vacher AM, Odessa MF, Dufy B, J Biomed Sci 1995 2 357 365 10.1007/BF02255223 11725073
46. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E, Prostate 1996 29 219 230 10.1002/(SICI)1097-0045(199610)29:4<219::AID- PROS3>3.0.CO;2-6 8876705 (Pubitemid 26365287)
47. Characterization of a new coculture model for BPH which expresses 5-alpha-reductase types I and II: the effects of Permixon on DHT formation (abstract 70). Bayne CW, Grant ES, Chapman K, Fourth International Consultation on BPH, Paris 1997 70